U.K. biopharma buys Homology Medicines' gene therapy manufacturing business
British gene and cell therapy firm Oxford Biomedica plc is buying Homology Medicines' gene therapy manufacturing business for $130 million up front to establish a new business. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 28, 2022 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City
Chimeron Bio expanding in Philadelphia; SwanBio making progress on its lead gene therapy candidate. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 28, 2022 Category: Biotechnology Authors: John George Source Type: news

Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patients
BEDFORD, Texas, Jan. 25, 2022 -- (Healthcare Sales & Marketing Network) -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced it received IND clearance from the ... Regenerative Medicine, Ophthalmology, FDA Nanoscope Therapeutics, Stargardt, optogenetic, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2022 Category: Pharmaceuticals Source Type: news

Viral Vectors Market Reaches $712 Million as Gene Therapy, COVID-19,...
Healthcare publisher, Kalorama Information, shares insights from its latest report on the Viral Vectors market.(PRWeb January 19, 2022)Read the full story at https://www.prweb.com/releases/viral_vectors_market_reaches_712_million_as_gene_therapy_covid_19_and_company_investments_create_growth/prweb18446761.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 19, 2022 Category: Pharmaceuticals Source Type: news

Krystal Biotech appoints new executive
Pittsburgh-based gene therapy company Krystal Biotech Inc. announced that it has appointed a new member to its executive leadership team. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 18, 2022 Category: Pharmaceuticals Authors: Jordyn Hronec Source Type: news

Center for Breakthrough Medicines signs $100M collaboration deal with Penn's gene therapy program
The Center for Breakthrough Medicines and the University of Pennsylvania ’s gene therapy program, led by Dr. Jim Wilson, signed a collaboration agreement Tuesday. Under the terms of the deal, Wilson’s laboratory at Penn will receive up to $100 million in sponsored research funding over 15 years. The renewable, five-year partnership combines Penn’s expertise in ge ne therapy development with the King of Prussia-based center's manufacturing capacity. The combination will allow the center to… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - January 18, 2022 Category: American Health Authors: John George Source Type: news

Beam Therapeutics inks deal with Pfizer worth up to $1.35B
Gene-editing firm Beam Therapeutics Inc. has signed a four-year deal worth up to $1.35 billion with pharmaceutical giant Pfizer Inc. Pfizer (NYSE: PFE) is paying Cambridge-based Beam (Nasdaq: BEAM) $300 million up front to develop gene therapies for three targets for rare diseases in the liver, muscle and central nervous system. Milestone payments to Beam could reach up to $1.05 billion. Pfizer will retain the options on exclu sive, global licenses for each development candidate; if it exercises (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 10, 2022 Category: Biotechnology Authors: Rowan Walrath Source Type: news

Castle Creek Biosciences withdraws IPO plans
The company had planned to use the proceeds from the stock sale for its cell and gene therapies targeting rare skin disorders. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 30, 2021 Category: American Health Authors: John George Source Type: news

2021 in Review: Greater Philadelphia's life sciences industry tops $1.1B in VC investments
Cell and gene therapy developers attracted most of the investment dollars, and the three largest deals accounted for more than half of the region's total. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 30, 2021 Category: American Health Authors: John George Source Type: news

High Price Tag for New, Long-Awaited Gene Therapies
Unfortunately, these treatments can cost hundreds of thousands to millions of dollars which puts a damper on celebration. (Source: WebMD Health)
Source: WebMD Health - December 30, 2021 Category: Consumer Health News Source Type: news

Gene Therapies Could Treat Rare Diseases — but Cost Millions Gene Therapies Could Treat Rare Diseases — but Cost Millions
A biotechnology and policy expert shines a light on the looming gene therapies soon to hit the market, and the payment strategies needed to get them to patients.Quick Take (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 29, 2021 Category: Internal Medicine Tags: Internal Medicine News Source Type: news

A Peninsula biotech's FDA approval could shift the health prognosis for people of color
This month has set up Global Blood Therapeutics for a long-term battle with emerging gene therapies in sickle cell disease. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - December 23, 2021 Category: Health Management Authors: Ron Leuty Source Type: news

The Past, Present, and Future of Cell and Gene Therapy
Embark on the journey of cell and gene therapy —from its conception and development, to its present state, and into its future. (Source: The Scientist)
Source: The Scientist - December 23, 2021 Category: Science Tags: Sponsored eBooks Source Type: news

UCLA gene therapy gives new life to girl born with fatal immune disorder
In every visible way, Marley Gaskins is an average 12-year-old — she enjoys painting, playing online games like Roblox with her friends and taking ukulele lessons. But until recently, her life was far from normal.Marley was born with a one-in-a-million genetic disorder called leukocyte adhesion deficiency-1, or LAD-1, which cripples the immune system and results in recurring infections, coupled with slow wound healing.“She started getting what looked like ant bites on her skin when she turned 1,” said Marley’s mother, Tamara Hogue. “When she was 3, she got a really big skin abscess on her stomach that landed her ...
Source: UCLA Newsroom: Health Sciences - December 17, 2021 Category: Universities & Medical Training Source Type: news

Lab Notes: Trevena advances new pain drug; Ocugen receives good news from FDA
Philadelphia-area life sciences news this week includes updates on a potential new pain medicine, a gene therapy candidate, and a key patent. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 17, 2021 Category: Biotechnology Authors: John George Source Type: news